
Dopamine D1 receptor antagonists - Pipeline Insight, 2024
Description
Dopamine D1 receptor antagonists - Pipeline Insight, 2024
DelveInsight’s, “Dopamine D1 Receptor Antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Dopamine D1 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Dopamine D1 Receptor Antagonists: Overview
Dopamine receptor D1, also known as DRD1, is a protein that in humans is encoded by the DRD1 gene. D1 receptors are the most abundant kind of dopamine receptor in the central nervous system.
Function - D1 receptors regulate the growth of neurons, mediate some behaviors, and modulate dopamine receptor D2-mediated events. They play a role in addiction by facilitating the gene expression changes that occur in the nucleus accumbens during addiction. They are Gs/a coupled and can stimulate neurons by indirectly activating cyclic AMP-dependent protein kinase.
Dopamine D1 Receptor Antagonists - Many typical and atypical antipsychotics are D1 receptor antagonists in addition to D2 receptor antagonists. No other D1 receptor antagonists have been approved for clinical use. Ecopipam is a selective D1-like receptor antagonist that has been studied clinically in humans in the treatment of a variety of conditions, including schizophrenia, cocaine abuse, obesity, pathological gambling, and Tourette's syndrome, with efficacy in some of these conditions seen. The drug produced mild-to-moderate, reversible depression and anxiety in clinical studies however and has yet to complete development for any indication.
Dopamine D1 Receptor Antagonists Emerging Drugs Chapters
This segment of the Dopamine D1 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dopamine D1 Receptor Antagonists Emerging Drugs
- Ecopipam (EBS-101): Emalex Biosciences
- Olanzapine (INP-105) : Impel Neuropharma
Further product details are provided in the report……..
Dopamine D1 Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Dopamine D1 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Dopamine D1 Receptor Antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Dopamine D1 Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dopamine D1 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dopamine D1 Receptor Antagonists drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Dopamine D1 Receptor Antagonists R&D. The therapies under development are focused on novel approaches for Dopamine D1 Receptor Antagonists.
- Dopamine D1 Receptor Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Dopamine D1 Receptor Antagonists drugs?
- How many Dopamine D1 Receptor Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Dopamine D1 Receptor Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dopamine D1 Receptor Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dopamine D1 Receptor Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Emalex Biosciences
- Impel Neuropharma
- Starton Therapeutics
- Fabre-Kramer Pharmaceuticals
- Intra-Cellular Therapies
- Ecopipam (EBS-101)
- INP-105
- STAR-OLZ
- FKF 02SC
- ITI 333
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Dopamine D1 Receptor Antagonists: Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Dopamine D1 Receptor Antagonists – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Dopamine D1 Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Dopamine D1 Receptor Antagonists Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Ecopipam (EBS-101): Emalex Biosciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- INP-105: Impel Neuropharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Dopamine D1 Receptor Antagonists Key Companies
- Dopamine D1 Receptor Antagonists Key Products
- Dopamine D1 Receptor Antagonists- Unmet Needs
- Dopamine D1 Receptor Antagonists- Market Drivers and Barriers
- Dopamine D1 Receptor Antagonists- Future Perspectives and Conclusion
- Dopamine D1 Receptor Antagonists Analyst Views
- Dopamine D1 Receptor Antagonists Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.